secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2026-07-21T12:30:30+00:00
Accession:  0001213900-26-079824
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics launches partnering process for late-stage cardiac critical care assets
--------------------------------------------------------------------------------

- Portfolio aligned into three pillars: Pre-Operative Safety (frunexian), Orphan Regulatory Acceleration (tecarfarin), Post-Operative Shield (CAD-1005).
- Phase 2 CAD-1005 data showed >25% absolute reduction in thrombotic events in heparin-induced thrombocytopenia patients.
- Seeking out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets.
- Also advancing oral 12-LOX inhibitor CAD-2000 for chronic cardiorenal inflammatory and thrombotic indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/0001213900-26-079824-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390026079824/ea0298669-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-079824

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer